survodutide
2 stories
-
healthBoehringer's Obesity Drug Shows Promising Weight Loss, Flagging Tolerability Concerns
Boehringer Ingelheim releases detailed phase 3 obesity drug data: 16.6% weight loss, significant liver fat reduction, but tolerability issues spark investor sell-off.
-
healthBoehringer Ingelheim Obesity Drug Shows Significant Weight Loss in Phase 3 Trial
Boehringer Ingelheim's investigational obesity therapy, survodutide, achieved up to 16.6% average weight loss in a Phase 3 trial, targeting appetite and liver metabolism.